Jump Financial LLC Cuts Stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Jump Financial LLC decreased its position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 47.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,700 shares of the company's stock after selling 23,411 shares during the period. Jump Financial LLC's holdings in Centessa Pharmaceuticals were worth $430,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of CNTA. GAMMA Investing LLC lifted its stake in Centessa Pharmaceuticals by 29.1% during the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock worth $64,000 after acquiring an additional 865 shares in the last quarter. Barclays PLC lifted its stake in Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after acquiring an additional 4,952 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Centessa Pharmaceuticals by 39.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company's stock worth $317,000 after acquiring an additional 5,316 shares in the last quarter. XTX Topco Ltd lifted its stake in Centessa Pharmaceuticals by 122.9% during the 4th quarter. XTX Topco Ltd now owns 22,680 shares of the company's stock worth $380,000 after acquiring an additional 12,506 shares in the last quarter. Finally, State Street Corp acquired a new position in Centessa Pharmaceuticals during the 3rd quarter worth about $777,000. Institutional investors and hedge funds own 82.01% of the company's stock.

Analyst Ratings Changes

CNTA has been the subject of several recent research reports. TD Cowen assumed coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a "buy" rating for the company. Piper Sandler initiated coverage on shares of Centessa Pharmaceuticals in a research note on Monday, March 31st. They issued an "overweight" rating and a $38.00 price target for the company. Guggenheim reissued a "buy" rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Finally, Morgan Stanley reissued an "overweight" rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $27.71.

Centessa Pharmaceuticals Stock Down 0.1 %

Shares of Centessa Pharmaceuticals stock traded down $0.01 during trading hours on Wednesday, hitting $13.71. The company had a trading volume of 553,595 shares, compared to its average volume of 610,862. The company's 50-day moving average is $14.26 and its two-hundred day moving average is $15.83. Centessa Pharmaceuticals plc has a twelve month low of $7.75 and a twelve month high of $19.09. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The company has a market cap of $1.83 billion, a P/E ratio of -8.96 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.04. Analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Insider Activity

In related news, insider David M. Chao sold 7,000 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $17.17, for a total transaction of $120,190.00. Following the completion of the sale, the insider now owns 225,007 shares in the company, valued at $3,863,370.19. This represents a 3.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Saurabh Saha sold 14,656 shares of the stock in a transaction on Monday, April 21st. The stock was sold at an average price of $12.29, for a total transaction of $180,122.24. Following the sale, the chief executive officer now owns 261,361 shares of the company's stock, valued at approximately $3,212,126.69. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 219,513 shares of company stock worth $3,576,685. Corporate insiders own 11.59% of the company's stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.